Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 147Melanoma 122Breast Neoplasms 98Squamous Cell Carcinoma of Head and Neck 96Triple Negative Breast Neoplasms 85Lung Neoplasms 64Neoplasm Metastasis 53Carcinoma, Renal Cell 49Neoplasms 46Head and Neck Neoplasms 46Colorectal Neoplasms 41Ovarian Neoplasms 38Carcinoma, Transitional Cell 36Carcinoma, Hepatocellular 36Pancreatic Neoplasms 35Urinary Bladder Neoplasms 34Recurrence 33Stomach Neoplasms 32Glioblastoma 30Brain Neoplasms 28Sarcoma 26Endometrial Neoplasms 25Prostatic Neoplasms 23Hodgkin Disease 22Uterine Cervical Neoplasms 19Fallopian Tube Neoplasms 19Carcinoma, Squamous Cell 19Esophageal Squamous Cell Carcinoma 17Adenocarcinoma 17Multiple Myeloma 16

Interventions

Gemcitabine 5Irinotecan 2Albumin-Bound Paclitaxel 2regorafenib 1pembrolizumab 1olaparib 1ibrutinib 1Tetrahydrouridine 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Decitabine 1Counseling 1Cisplatin 1Capecitabine 1BKT140 14-fluorobenzoyl-TN-14003 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Pancreatic Adenocarcinoma × pembrolizumab × Clear all
NCT02907099 2025-02-19

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
20 enrolled 12 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡